AQR Capital Management LLC Has $4.42 Million Position in Novo Nordisk A/S (NYSE:NVO)

AQR Capital Management LLC grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 0.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 51,341 shares of the company’s stock after purchasing an additional 353 shares during the quarter. AQR Capital Management LLC’s holdings in Novo Nordisk A/S were worth $4,416,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in NVO. Diversified Trust Co raised its position in Novo Nordisk A/S by 13.9% during the 4th quarter. Diversified Trust Co now owns 3,246 shares of the company’s stock worth $279,000 after purchasing an additional 395 shares during the last quarter. ORG Partners LLC lifted its stake in shares of Novo Nordisk A/S by 181.7% in the fourth quarter. ORG Partners LLC now owns 1,003 shares of the company’s stock worth $86,000 after acquiring an additional 647 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in Novo Nordisk A/S by 0.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 290,489 shares of the company’s stock valued at $24,988,000 after acquiring an additional 1,051 shares during the last quarter. A. D. Beadell Investment Counsel Inc. increased its position in Novo Nordisk A/S by 41.1% during the 4th quarter. A. D. Beadell Investment Counsel Inc. now owns 13,012 shares of the company’s stock valued at $1,119,000 after purchasing an additional 3,787 shares during the period. Finally, Ridgewood Investments LLC bought a new position in Novo Nordisk A/S during the 4th quarter worth approximately $58,000. 11.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on NVO shares. Guggenheim cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 17th. Hsbc Global Res upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, April 28th. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. BNP Paribas initiated coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an “underperform” rating for the company. Finally, BMO Capital Markets restated a “market perform” rating and set a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $135.00.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $65.75 on Friday. The business’s fifty day moving average is $69.21 and its 200 day moving average is $86.23. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The stock has a market cap of $295.06 billion, a P/E ratio of 19.98, a P/E/G ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.92. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $79.17 billion. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.